Background Cytomegalovirus (CMV) is a leading cause of congenital infection and an
important target for vaccine development. Methods CMV seronegative girls between 12 and …

Background. Immunization of young children against cytomegalovirus (CMV) might
decrease child-to-child and child-to-adult transmission of CMV and thereby reduce maternal …

A vaccine comprised of recombinant cytomegalovirus (CMV) envelope glycoprotein B (gB)
with MF59 adjuvant developed in the 1990s recently was recently found to have efficacy for …

Abstract Development of a vaccine for prevention of congenital cytomegalovirus (CMV)
disease is a priority. This study evaluated a “prime-boost” strategy by comparing the safety …

Background Congenital infection with cytomegalovirus (CMV) is an important cause of
hearing, cognitive, and motor impairments in newborns. Methods In this phase 2, placebo …

Human cytomegalovirus (HCMV) is ubiquitous in all populations, and is the most commonly
recognized cause of congenital viral infection in developed countries. On the basis of the …

Congenital cytomegalovirus (CMV) infection is the most common infectious cause of
disability in newborn infants. CMV also causes serious disease in solid organ (SOT) and …

ABSTRACT A vaccine against congenital human cytomegalovirus (CMV) infection is a major
public health priority. Congenital CMV causes substantial long-term morbidity, particularly …

Congenital human cytomegalovirus (HCMV) infection can result in severe and permanent
neurological injury in newborns, and vaccine development is accordingly a major public …

Human cytomegalovirus (CMV) is the most common infectious cause of infant brain damage
and posttransplant complications worldwide. Despite the high global burden of disease …